Transendocardial CD34+ Cell Therapy does not Increase the Risk of Ventricular Arrhythmias in Patients with Chronic Heart Failure
Ventricular arrhythmias (VA) are of major concern in the field of cell therapy, potentially limiting its safety and efficacy. We sought to investigate the effects of CD34 + cell therapy on VA burden in patients with chronic heart failure (CHF). We performed registry data analysis of patients with CH...
Main Authors: | Gregor Poglajen, Gregor Zemljič, Andraž Cerar, Sabina Frljak, Martina Jaklič, Vesna Androcec, Bojan Vrtovec |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-07-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.1177/0963689719840351 |
Similar Items
-
Transendocardial CD34 Cell Therapy Improves Local Mechanical Dyssynchrony in Patients With Nonischemic Dilated Cardiomyopathy
by: Neža Žorž, et al.
Published: (2022-03-01) -
Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Gregor Poglajen, et al.
Published: (2020-07-01) -
Cell Therapy in Heart Failure with Preserved Ejection Fraction
by: Sabina Frljak, et al.
Published: (2022-03-01) -
Impairment of myocardial perfusion correlates with heart failure severity in patients with non‐compaction cardiomyopathy
by: Andraz Cerar, et al.
Published: (2020-06-01) -
Response to the letter to the editor: unravel the genetic background of noncompaction before relating it with myocardial hypoperfusion
by: Andraz Cerar, et al.
Published: (2020-08-01)